GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (FRA:EWL) » Definitions » EV-to-EBIT

Edwards Lifesciences (FRA:EWL) EV-to-EBIT : 31.18 (As of May. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Edwards Lifesciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Edwards Lifesciences's Enterprise Value is €46,737 Mil. Edwards Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €1,499 Mil. Therefore, Edwards Lifesciences's EV-to-EBIT for today is 31.18.

The historical rank and industry rank for Edwards Lifesciences's EV-to-EBIT or its related term are showing as below:

FRA:EWL' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.69   Med: 28.82   Max: 68.19
Current: 30.94

During the past 13 years, the highest EV-to-EBIT of Edwards Lifesciences was 68.19. The lowest was 10.69. And the median was 28.82.

FRA:EWL's EV-to-EBIT is ranked worse than
68.7% of 460 companies
in the Medical Devices & Instruments industry
Industry Median: 20.355 vs FRA:EWL: 30.94

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Edwards Lifesciences's Enterprise Value for the quarter that ended in Mar. 2024 was €52,710 Mil. Edwards Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €1,499 Mil. Edwards Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2.84%.


Edwards Lifesciences EV-to-EBIT Historical Data

The historical data trend for Edwards Lifesciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences EV-to-EBIT Chart

Edwards Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.38 60.32 46.54 25.11 27.82

Edwards Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.95 31.80 23.43 27.82 34.94

Competitive Comparison of Edwards Lifesciences's EV-to-EBIT

For the Medical Devices subindustry, Edwards Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's EV-to-EBIT falls into.



Edwards Lifesciences EV-to-EBIT Calculation

Edwards Lifesciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=46736.540/1498.688
=31.18

Edwards Lifesciences's current Enterprise Value is €46,737 Mil.
Edwards Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,499 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Edwards Lifesciences  (FRA:EWL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Edwards Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=1498.688/52709.9
=2.84 %

Edwards Lifesciences's Enterprise Value for the quarter that ended in Mar. 2024 was €52,710 Mil.
Edwards Lifesciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,499 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Edwards Lifesciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Edwards Lifesciences (FRA:EWL) Business Description

Address
One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.